sarepta ceo on what's next after expanded muscular dystrophy drug approval
Published 11 days ago • 1.6K plays • Length 5:43Download video MP4
Download video MP3
Similar videos
-
1:44
sarepta soars on expanded approval for muscular dystrophy drug
-
3:18
sarepta therapeutics ceo on soaring stock and drug development
-
3:51
td cowen's ritu bara talks sarepta stock skyrocketing on fda gene therapy approval
-
2:47
sarepta shares tumble as concerns mount over fda approval on gene therapy
-
4:09
watch cnbc's full interview with sarepta ceo doug ingram
-
3:31
sarepta ceo doug ingram: we should be profitable by the end of next year if we achieve our goals
-
3:43
fda board votes to approve gene therapy for duchenne muscular dystrophy
-
5:00
sarepta (srpt) soars on fda approval on muscular dystrophy treatment
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
2:46
scientists restore muscle strength in dogs using micro-dystrophin gene therapy
-
3:31
duchenne muscular dystrophy (dmd) mechanism of disease
-
18:41
in the pipeline: gene therapy - sarepta therapeutics
-
4:28
gene therapy trial in muscular dystrophy patients shows exciting results
-
6:41
former fda commissioner dr. scott gottlieb on the future of gene therapy
-
5:00
biotech analyst discusses her top stock picks: biogen & sarepta therapeutics
-
18:37
in the pipeline: restoring dystrophin - sarepta therapeutics (rna targeted therapies)
-
0:39
sarepta working on groundbreaking gene therapies in central ohio
-
46:01
webinar: envision study update with sarepta therapeutics
-
35:04
trials in duchenne - sarepta [ppmd's 2016 connect conference]
-
51:20
community webinar series 2020: meet sarepta therapeutics
-
52:45
[webinar] community discussion with sarepta therapeutics - august 2019
-
1:01:36
[webinar] introducing ppmo – sarepta therapeutics – may 2018